Azitra said it is expanding into the consumer skin-care market as it continues development of its clinical pipeline.
Branford-based biotech company Azitra said it is expanding into the consumer skin-care market as it continues development of its clinical pipeline, while reporting a wider first-quarter net loss.
The clinical-stage company said Wednesday it has launched new protein and peptide programs for cosmetic markets using its filaggrin technology, which is based on a skin-barrier protein associated with hydration and skin health. The company said the initiative will target products aimed at improving the appearance of fine lines, wrinkles and dry skin.
Azitra also said it added MD Anderson Cancer Center as a clinical site for its Phase 1/2 trial of ATR-04, a treatment candidate for skin rash associated with certain cancer therapies.
Azitra on Wednesday also disclosed its first quarter financial results. For the quarter ended March 31, the company reported a net loss of $3.9 million, or 25 cents per diluted share, compared with a loss of $3.1 million, or $1.55 per diluted share, in the year-ago period.
Research and development expenses rose to $1.6 million from $1.3 million, while general and administrative expenses increased to $2.4 million from $1.9 million.
Azitra reported $10.1 million in cash and cash equivalents as of March 31, up from $2.1 million at the end of 2025.
